Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Adverse events related to the eradication medication is one of the reason of lower eradication success in the H. pylori treatment. The aim of this study was to evaluate the additive effect of trimebutine for the development of adverse events related to the H. pylori eradication regimen.
Adverse events related to the eradication medication is one of the reason of lower eradication success in the H. pylori treatment. The common adverse events related to the eradication medications area as follows; Abdomen discomfort, pain, nausea, vomiting, diarrhea, bloating, urticaria, dizziness, headache, etc,. Various methods have been tried to reduce or prevent the adverse events related to the eradication medications. However, there is no established methods to reduce or prevent these events.
The aim of this study was to evaluate the additive effect of trimebutine for the development of adverse events related to the H. pylori eradication regimen.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Trimebutine add group | Experimental | Addition of Trimebutine on the Bismuth-containing quadruple regimen |
|
| Control group | No Intervention | Bismuth-containing quadruple regimen |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trimebutine 100 MG | Drug | Trimebutine 100mg three times a day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall compliance of eradication medication | How much the enrolled subjects took prescribed eradication medication | 2 weeks after prescription of eradication medication |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events related to eradication medication | percentage of Adverse events related to eradication medication | 2 weeks and 6 weeks after prescription of eradication medication |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chang Seok Bang, MD, PHD | Hallym University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chuncheon Sacred Heart hospital | Chuncheon | Gangwon-do | 24253 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014287 | Trimebutine |
| ID | Term |
|---|---|
| D062425 | Hydroxybenzoate Ethers |
| D062385 | Hydroxybenzoates |
| D001565 | Benzoates |
| D000146 | Acids, Carbocyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D002264 |
| Carboxylic Acids |
| D009930 | Organic Chemicals |
| D006880 | Hydroxy Acids |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D010647 | Phenyl Ethers |
| D010636 | Phenols |